Discover the best CRM for Outlook integration to enhance your productivity. Compare different solutions and explore your ...

Mr. Kenyon has served as the Company’s Chief Financial Officer and Secretary since September 2015. He has been a member of Outlook Therapeutics’ board of directors since August 2018 and also served as ...

Outlook Therapeutics (OTLK) announced that Russell Trenary has stepped down as the company’s president and CEO, effective immediately. Lawrence ...

Shares of AT&T Inc. T rose sharply during Tuesday's session after the company updated its 2024 guidance, raising the bottom ...

Fintel reports that on December 2, 2024, UBS downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) from Buy to ...

Fintel reports that on December 2, 2024, Chardan Capital downgraded their outlook for Outlook Therapeutics (NasdaqCM:OTLK) from Buy to Neutral. Analyst Price Forecast Suggests 1,865.37% Upside As of ...

In the assessment of 12-month price targets, analysts unveil insights for Voyager Therapeutics, presenting an average target ...

Outlook Therapeutics (NASDAQ:OTLK – Free Report) had its target price reduced by BTIG Research from $50.00 to $9.00 in a ...

Brookline Capital Management cut their FY2025 earnings per share (EPS) estimates for Outlook Therapeutics in a report issued ...

On Friday, Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $1.97 which represents a slight increase of $0.27 or 15.88% from the prior close of $1.7. The stock opened at $1 ...

BTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The ...

PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...